Gilead Sciences, Inc.
NASDAQ:GILDDrug Manufacturers - General
-$2.69 today
- Market cap
- $209.59B
- Beta
- 0.33
- P/E (TTM)
- 16.5
- EPS (TTM)
- $7.42
- Dividend yield
- 2.62%
Volume 4.82M
Average 6.78M
GILD Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Gilead Sciences, Inc.NASDAQ: GILD
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income turns negative
Q2 FY2026 operating income was -$10.39B, compared with $2.47B a year earlier. Trailing-twelve-month operating income was -$1.49B. Over 3 fiscal years it compounded at +16.9% a year.
Context
- Operating income amounted to 39.7% of revenue in FY2025, up 34.0 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 18 analysts of -$259M (-102.2%) for the fiscal year ending Dec 2026, a slowdown from the +604.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$10.39B-501.9% QoQ
- Last fiscal yearDec 2025
- $11.7B+604.0% YoY
- LTMJun 2026
- -$1.49B-118.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 11.7B USD
- Year-over-year change
- +604.0%
- 4-year CAGR
- +4.2%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.7B | +604.0% |
| FY2024 | 2024-12-31 | 1.66B | -78.1% |
| FY2023 | 2023-12-31 | 7.61B | +3.8% |
| FY2022 | 2022-12-31 | 7.33B | -26.1% |
| FY2021 | 2021-12-31 | 9.92B | — |
Operating Income vs competitors
How GILD compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -118.5% is the lowest of 10, against a peer median of +6.2%.
- Operating income amounts to 4.9% of revenue for GILD, versus a peer median of 25.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $39.61B USD | +76.5% | +50.8% | 49.7% | |
| LTM Sep 2026 | $25.53B USD | +6.2% | +6.8% | 25.7% | |
| LTM Sep 2026 | $23.46B USD | +159.5% | +3.5% | 35.5% | |
| LTM Jun 2026 | $17.02B USD | +2.2% | -23.0% | 26.7% | |
| LTM Jun 2026 | $16.99B USD | +1.8% | +29.0% | 30.5% | |
| LTM Sep 2026 | $14.71B USD | +14.9% | +54.1% | 23.7% | |
| LTM Jun 2026 | $11.06B USD | -48.3% | +8.7% | 16.7% | |
| LTM Jun 2026 | €7.24B EUR | -8.6% | -1.9% | 14.8% | |
| LTM Jun 2026 | £6.87B GBP | +34.1% | +9.0% | 20.7% | |
| LTM Jun 2026 | -$1.49B USD | -118.5% | +16.9% | 4.9% | |
| Peer median (excluding GILD) | — | +6.2% | +8.7% | 25.7% | |
Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.31B | 27.28B | 27.12B | 28.75B | 29.44B |
| Cost of Revenue | 6.6B | 5.66B | 6.5B | 6.25B | 6.23B |
| Gross Profit | 20.7B | 21.62B | 20.62B | 22.5B | 23.21B |
| Gross Margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Research & Development | 4.6B | 4.98B | 5.72B | 5.91B | 5.8B |
| Selling, General & Admin | 5.25B | 5.67B | 6.09B | 6.09B | 5.71B |
| Operating Expenses | 10.79B | 14.29B | 13.01B | 20.84B | 11.51B |
| Depreciation & Amortization | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B |
| EBITDA | 11.33B | 8.85B | 10.5B | 4.43B | 13.58B |
| EBITDA Margin | 41.5% | 32.4% | 38.7% | 15.4% | 46.1% |
| Operating Income | 9.92B | 7.33B | 7.61B | 1.66B | 11.7B |
| Operating Margin | 36.3% | 26.9% | 28.0% | 5.8% | 39.7% |
| Interest Income | 0 | 106M | 376M | 281M | 349M |
| Interest Expense | 1B | 935M | 944M | 977M | 1.02B |
| Other Income / Expenses | (1.64B) | (1.52B) | (746M) | (972M) | (1.91B) |
| Income Before Tax | 8.28B | 5.81B | 6.86B | 690M | 9.8B |
| Pre-Tax Margin | 30.3% | 21.3% | 25.3% | 2.4% | 33.3% |
| Income Tax Expense | 2.08B | 1.25B | 1.25B | 211M | 1.29B |
| Net Income | 6.23B | 4.59B | 5.67B | 480M | 8.51B |
| Net Margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| EPS (Basic) | 4.96 | 3.66 | 4.54 | 0.38 | 6.84 |
| EPS (Diluted) | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| Weighted Avg Shares | 1.26B | 1.26B | 1.25B | 1.25B | 1.24B |
| Weighted Avg Shares (Diluted) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B |
Gilead Sciences, Inc.
NASDAQ:GILD
Intrinsic Alpha fair value
Locked
Current Price
$168.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.